Is JVInvest stock valuation data free and transparent?

Yes, all valuation data on JVInvest is 100% free and transparent. We provide verifiable P/E ratios for the Top 100 global stocks, S&P 500, Nasdaq 100, and major indices worldwide. All data sources are disclosed so you can verify every calculation yourself.

What valuation metrics are available on JVInvest?

JVInvest provides transparent P/E ratios for Top 100 global stocks (MSCI World), S&P 500, Nasdaq 100, DAX, FTSE 100, Nikkei 225 and more. All valuation metrics are verifiable with disclosed quarterly EPS data and market prices.

Do I need to create an account to access the data?

No account or signup is required. All S&P 500 fundamental data is freely accessible without registration.

How can I verify the P/E ratio calculations?

All our valuation data is 100% transparent. We disclose all data sources, quarterly EPS figures, and market prices used in calculations. You can verify every P/E ratio yourself using our transparent methodology.

What is a Sankey chart for stocks?

A Sankey chart visualizes the flow of money through a company's financial statements - showing how revenue flows to costs, operating income, net income, and cash flows. JVInvest offers free Sankey charts for all S&P 500 companies.

Which stock indices have free valuation data?

JVInvest provides free, verifiable valuation data for major global indices: S&P 500, Nasdaq 100, DAX 40, FTSE 100, CAC 40, Nikkei 225, and the Top 100 MSCI World stocks. All index P/E ratios are calculated transparently.

What is the current S&P 500 P/E ratio?

JVInvest calculates and displays the current S&P 500 index P/E ratio based on the aggregate earnings of all constituent companies. Visit the Valuation page for the latest P/E ratio data.

Daily Market Report – February 23, 2026

Name: Transparent Stock Valuation Data (English & German)
Creator: JVInvest
License: https://creativecommons.org/licenses/by/4.0/

The financial markets switched to "risk-off" mode on Monday, February 23, 2026: Following the renewed escalation of US tariff policy – this time as a temporary global 15% tariff – concerns about new trade uncertainties prevailed across time zones. Accordingly, the major stock indices in the US and Europe declined, while defensive segments remained relatively stable.

Among the global heavyweights, Novo Nordisk OMXCOP:NOVO_B stood out today with a price drop of well over 15% – triggered by disappointing study data on the obesity candidate CagriSema.

US Treasury bonds were in demand, the 10-year Treasury yields TVC:US10Y and the US dollar declined, while the Euro FX:EURUSD showed strength. Gold OANDA:XAUUSD surged significantly as a hedge against political and trade policy shocks.

Täglicher Marktbericht – 23. Februar 2026

Die Finanzmärkte haben am Montag, dem 23. Februar 2026, in den „Risk-off“-Modus geschaltet: Nach der erneuten Eskalation der US-Zollpolitik – diesmal als befristeter globaler 15%-Tarif – überwog quer über Zeitzonen die Sorge vor neuer Handelsunsicherheit. Entsprechend gaben die großen Aktienindizes in den USA und Europa nach, während defensive Segmente vergleichsweise stabil blieben.

Unter den globalen Schwergewichten stach heute vor allem Novo Nordisk OMXCOP:NOVO_B mit einem Kurseinbruch von deutlich über 15% hervor – ausgelöst durch enttäuschende Studiendaten zum Adipositas-Kandidaten CagriSema.

US-Staatsanleihen waren gesucht, die 10-jährigen Treasury Renditen TVC:US10Y und der US-Dollar gaben nach, der Euro FX:EURUSD zeigte sich fester. Gold OANDA:XAUUSD sprang als Versicherung gegen politische und handelspolitische Schocks deutlich an.